A rush of transactions is transforming the industry, as blockbuster medicines lose patent protection. The latest acquisition cost AbbVie 16 percent of its share price. Source: NYT > Business – Stephen Grocer
Big Pharma’s Hunt for New Drugs Is Pushing Up Cost of Deals
Just two months into the year, the value of acquisitions of American biotech companies has already exceeded last year’s total. Source: NYT > Business – STEPHEN GROCER